PL4199922T3 - Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych - Google Patents

Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych

Info

Publication number
PL4199922T3
PL4199922T3 PL21765908.5T PL21765908T PL4199922T3 PL 4199922 T3 PL4199922 T3 PL 4199922T3 PL 21765908 T PL21765908 T PL 21765908T PL 4199922 T3 PL4199922 T3 PL 4199922T3
Authority
PL
Poland
Prior art keywords
phenylthiazol
cyclopentane
carbamoyl
cyano
treatment
Prior art date
Application number
PL21765908.5T
Other languages
English (en)
Polish (pl)
Inventor
Julio CASTRO- PALOMINO LARIA
Juan CAMACHO GÓMEZ
Nahomi CASTRO-PALOMINO LARIA
Alina ARIOSA ÁLVAREZ
Original Assignee
Palobiofarma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma, S.L. filed Critical Palobiofarma, S.L.
Publication of PL4199922T3 publication Critical patent/PL4199922T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL21765908.5T 2020-08-21 2021-08-20 Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych PL4199922T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
PL4199922T3 true PL4199922T3 (pl) 2025-02-10

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21765908.5T PL4199922T3 (pl) 2020-08-21 2021-08-20 Kwas (1r,3s)-3-((5-cyjano-4-fenylotiazol-2-ilo)karbamoilo)cyklopentano-1-karboksylowy do stosowania w leczeniu chorób dróg oddechowych

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
AU2015315628A1 (en) * 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Also Published As

Publication number Publication date
JP2023538419A (ja) 2023-09-07
AU2021327728B2 (en) 2026-06-11
WO2022038261A1 (en) 2022-02-24
DK4199922T3 (da) 2024-11-25
CA3190081A1 (en) 2022-02-24
KR20230054444A (ko) 2023-04-24
RS66263B1 (sr) 2024-12-31
EP3957308A1 (en) 2022-02-23
BR112023002778A2 (pt) 2023-03-14
HRP20241621T1 (hr) 2025-01-31
CN115942933A (zh) 2023-04-07
SI4199922T1 (sl) 2025-03-31
US20230321053A1 (en) 2023-10-12
PT4199922T (pt) 2024-12-18
AU2021327728A1 (en) 2023-03-09
LT4199922T (lt) 2025-01-10
MX2023002156A (es) 2023-03-01
EP4199922A1 (en) 2023-06-28
EP4199922B1 (en) 2024-09-25
JP7794807B2 (ja) 2026-01-06
ES3001104T3 (es) 2025-03-04
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
MX2024010140A (es) Nuevos metodos.
TW202619727A (zh) 使用jak抑制劑治療化膿性汗腺炎
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX387115B (es) Métodos para tratar la influenza.
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
IL285238A (en) Gene therapy vectors for treatment of danon disease
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
DK4199922T3 (da) (1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentan-1-carbonsyre til anvendelse i behandlingen af luftvejssygdomme
EP4566629A3 (en) Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages
PL3813816T3 (pl) Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x
EP4426686A4 (en) N,N-DIMETHYLAMPHTAMIN ANALOGUES FOR THE TREATMENT OF CEREBRAL DISORDERS
AR119159A1 (es) Tratamientos de angioedema
EP4096628C0 (en) USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE INHALATION TREATMENT OF INFLAMMATORY PULMONARY DISEASES
EP4221704A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES
IL288793A (en) Compounds for treating respiratory disease
EP3689327C0 (fr) Composition pharmaceutique dans le traitement de lésions pulmonaires
LT4182311T (lt) 1-metil-1h-pirazol-3-ilo dariniai, skirti naudoti neovaskulinių ligų gydymui
WO2016049580A3 (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
EA202090452A1 (ru) Соединения для лечения болезни фон гиппеля-линдау